Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.
Oka
Satoko
S
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan. in1230@poh.osaka-med.ac.jp
Yokote
Taiji
T
Akioka
Toshikazu
T
Hara
Satoshi
S
Kobayashi
Kichinosuke
K
Hirata
Yuji
Y
Hiraoka
Nobuya
N
Tsuji
Motomu
M
Hanafusa
Toshiaki
T
D000208:Acute Disease / Q000145:classification / Q000628:therapy; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004314:Down Syndrome / Q000097:blood* / Q000473:pathology*; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000145:classification / Q000235:genetics* / Q000628:therapy; D008297:Male; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide